Skip to main content

Table 1 Clinical characteristics of the study patients

From: Platelet volume indices are associated with systolic and diastolic cardiac dysfunction, and left ventricular hypertrophy

Variables

Women (n = 331)

Men (n = 910)

Age, years

71.1 ± 10.9

68.3 ± 10.8

Body mass index, kg/m2

22.9 ± 4.1

23.7 ± 3.5

Chronic hemodialysis, n (%)

8 (2.4)

45 (4.9)

Ever smoker

55 (16.6)

721 (79.2)

Cardiac rhythm

  

 Sinus rhythm, n (%)

258 (77.9)

750 (82.4)

 Atrial fibrillation, n (%)

45 (13.6)

107 (11.8)

 Pacemaker, n (%)

17 (5.1)

38 (4.2)

 Others, n (%)

11 (3.3)

15 (1.6)

Cardiovascular disease

  

 Ischemic heart disease, n (%)

173 (52.3)

681 (74.8)

 Arrhythmic disease, n (%)

35 (10.6)

70 (7.7)

 Cardiomyopathy, n (%)

113 (34.1)

217 (23.8)

 Peripheral artery disease, n (%)

15 (4.5)

82 (9.0)

 Valvular heart disease, n (%)

34 (10.3)

71 (7.8)

Medication

  

 ACE inhibitors/ARB, n (%)

150 (45.3)

524 (57.6)

 Beta blockers, n (%)

123 (37.2)

372 (40.9)

 Calcium channel blockers, n (%)

162 (48.9)

389 (42.7)

 Loop diuretics, n (%)

102 (30.8)

202 (22.2)

 Thiazide diuretics, n (%)

25 (7.6)

38 (4.2)

 Aldosterone antagonist, n (%)

35 (10.6)

79 (8.7)

 Aspirin, n (%)

166 (50.2)

658 (72.3)

 Clopidogrel, n (%)

88 (26.6)

393 (43.2)

 Any antiplatelet drug, n (%)

176 (53.2)

689 (75.7)

 Warfarin, n (%)

78 (23.6)

202 (22.2)

 NOAC, n (%)

40 (12.1)

79 (8.7)

 Any anticoagulants, n (%)

118 (35.6)

281 (30.9)

Laboratory data

  

 White blood cell count, x103/μL

5.67 (4.60–6.86)

6.07 (4.98–7.27)

 Hemoglobin, g/dL

12.4 (11.2–13.5)

13.6 (12.3–14.8)

 Platelet count, x103/μL

212 (172–259)

201 (171–239)

 Mean platelet volume, fL

8.1 (7.7–8.7)

8.2 (7.7–8.8)

 Platelet distribution width, %

52.0 (47.3–56.2)

53.1 (48.3–58.0)

 Serum creatinine, mg/dL

0.72 (0.62–0.93)

0.92 (0.80–1.13)

 eGFR, mL/min/1.73 m2

60.4 (45.9–71.8)

47 (37.3–55.9)

Echocardiographic data

  

 LV diastolic dimension, cm

4.6 (4.2–5.1)

4.9 (4.6–5.5)

 LV systolic dimension, cm

2.9 (2.5–3.5)

3.3 (2.9–3.9)

 LV ejection fraction, %

61 (54–68)

59 (51.0–65)

 LV mass index, g/m2

99 (83–123)

106 (89.9–128)

  1. ACE, angiotensin converting enzyme; ARB, angiotensin receptor blockers; NOAC, non-warfarin novel oral anticoagulants. For the data of serum creatinine and eGFR, patients on chronic hemodialysis (n = 53) were excluded from the analysis